<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322023</url>
  </required_header>
  <id_info>
    <org_study_id>U01MH074356</org_study_id>
    <secondary_id>U01MH074356</secondary_id>
    <secondary_id>DATR A5-EPTD</secondary_id>
    <nct_id>NCT00322023</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of D-serine in Schizophrenia</brief_title>
  <official_title>PK/PD Study of Escalating Dose D-serine as Adjunctive Treatment in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine whether increasing D-serine within the body will improve negative&#xD;
      symptoms and cognitive impairments in people with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a life-long brain disorder affecting approximately 1 percent of Americans&#xD;
      each year. Schizophrenia can be extremely disabling, causing people to hear voices,&#xD;
      experience paranoia or hallucinations, believe that others are controlling their thoughts,&#xD;
      and even fail at maintaining a job or caring for themselves. Current medications help to&#xD;
      relieve most of these symptoms, but not all. Some people with schizophrenia still suffer from&#xD;
      negative symptoms, such as difficulty with talking, expressing emotions, and motivation; they&#xD;
      may also suffer from cognitive impairments, such as decreased concentration and memory loss.&#xD;
      D-serine, an amino acid found within the body, activates brain cell receptors that appear to&#xD;
      play a role in learning and memory. This study will determine whether adding a D-serine&#xD;
      solution to a stable antipsychotic medication regimen will decrease negative symptoms in&#xD;
      people with schizophrenia.&#xD;
&#xD;
      Participants in this open-label study will remain on their regular medication regimen for at&#xD;
      least 2 weeks. During this time and before starting treatment, participants will be&#xD;
      interviewed about their emotional problems, marital status, education, family background,&#xD;
      employment history, and any drug or alcohol problems. Participants will also undergo a&#xD;
      physical exam, an electrocardiogram (EKG), vital sign measurements, psychological tests,&#xD;
      cognitive tasks, and an electroencephalogram (EEG). Participants will then begin 4 weeks of&#xD;
      treatment with D-serine. In addition to participants' regular medication regimen, they will&#xD;
      drink a D-serine powder mixed with water twice daily. Every 2 weeks, participants will&#xD;
      undergo a physical exam and an interview about any changes in symptoms or emotional problems&#xD;
      that they may be experiencing. Blood and urine samples will be taken throughout the study.&#xD;
      After 4 weeks, participants will undergo an EKG, EEG, and the same psychological tests and&#xD;
      cognitive tasks completed prior to treatment. A follow-up visit will occur 2 weeks&#xD;
      post-treatment to monitor any changes in negative symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal Safety Measures</measure>
    <time_frame>Measured at Week 4</time_frame>
    <description>number of renal adverse events (serum and urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Symptoms Scale (PANSS)</measure>
    <time_frame>Measured at Week 4</time_frame>
    <description>Absolute Change in PANSS over four weeks (change between baseline and final measurements). The PANSS is a 30-item rating scale widely used in assessment of medication effects in schizophrenia. The PANSS ranges from 30-210, with lower scores showing less symptoms. Larger change is better.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery</measure>
    <time_frame>Measured at Week 4</time_frame>
    <description>Change over 4 weeks. The MATRICS is a scale measuring cognition, and reported as T-score, with 50 as the population average and every 10 points representing a change of 1 standard deviation from the population average. Higher scores represent an improvement</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>D-serine 30 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-serine 30 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-serine 60 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-serine 60 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D-serine 120 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-serine 120 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <description>D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.</description>
    <arm_group_label>D-serine 120 mg/kg</arm_group_label>
    <arm_group_label>D-serine 30 mg/kg</arm_group_label>
    <arm_group_label>D-serine 60 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <arm_group_label>D-serine 30 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <arm_group_label>D-serine 60 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <arm_group_label>D-serine 120 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Structured Clinical Interview for DSM-III-R diagnosis of schizophrenia or&#xD;
             schizoaffective disorder&#xD;
&#xD;
          -  PANSS 3 factor negative symptom inclusion score greater than 20 prior to study entry&#xD;
&#xD;
          -  PANSS total score between 60 and 110&#xD;
&#xD;
          -  Simpson-Angus Scale total score of 12 or less&#xD;
&#xD;
          -  Calgary Depression Inventory total score of 10 and suicide score less than 2&#xD;
&#xD;
          -  No change in Clinical Global Impressions (CGI) Scale score prior to study entry&#xD;
&#xD;
          -  Chlorpromazine (CPZ) equivalent of 1500 or less&#xD;
&#xD;
          -  Willing to use an effective form of birth control throughout the study if sexually&#xD;
             active&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High extrapyramidal symptom (EPS) levels&#xD;
&#xD;
          -  Began, discontinued, or adjusted psychotropic medication within 2 weeks of study entry&#xD;
&#xD;
          -  Taking investigational medication within 2 weeks of study entry&#xD;
&#xD;
          -  Contraindication to study medication&#xD;
&#xD;
          -  Serious or unstable medical illness&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Alcohol or drug abuse within 6 months of study entry&#xD;
&#xD;
          -  Diagnosed with neurodegenerative disease or a seizure disorder&#xD;
&#xD;
          -  History of a kidney impairment&#xD;
&#xD;
          -  Currently taking clozapine&#xD;
&#xD;
          -  Currently taking more than two antipsychotic medications&#xD;
&#xD;
          -  Currently taking stimulants or cholinesterase inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C. Javitt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Kline Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Nathan S. Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 2, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2006</study_first_posted>
  <results_first_submitted>May 29, 2012</results_first_submitted>
  <results_first_submitted_qc>September 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2020</results_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Mental Health (NIMH)</investigator_affiliation>
    <investigator_full_name>Daniel C. Javitt, MD, PhD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Negative symptoms</keyword>
  <keyword>NMDA</keyword>
  <keyword>Glutamate</keyword>
  <keyword>Glycine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Nathan Kline Institute, Yale University, Zucker Hillside</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>D-serine 30 mg/kg</title>
          <description>Open label, adjunctive to antipsychotics for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>D-serine 60 mg/kg</title>
          <description>Open label, adjunctive to antipsychotics for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>D Serine 120 mg/kg</title>
          <description>Open label, adjunctive to antipsychotics for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>various</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>D-serine 30 mg/kg</title>
        </group>
        <group group_id="B2">
          <title>D-serine 60 mg/kg</title>
        </group>
        <group group_id="B3">
          <title>D Serine 120 mg/kg</title>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="11.4"/>
                    <measurement group_id="B2" value="43.9" spread="9.4"/>
                    <measurement group_id="B3" value="43.2" spread="9.6"/>
                    <measurement group_id="B4" value="43" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Renal Safety Measures</title>
        <description>number of renal adverse events (serum and urinalysis)</description>
        <time_frame>Measured at Week 4</time_frame>
        <population>study completers</population>
        <group_list>
          <group group_id="O1">
            <title>D-serine 30 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
          <group group_id="O2">
            <title>D-serine 60 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
          <group group_id="O3">
            <title>D Serine 120 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Safety Measures</title>
          <description>number of renal adverse events (serum and urinalysis)</description>
          <population>study completers</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Symptoms Scale (PANSS)</title>
        <description>Absolute Change in PANSS over four weeks (change between baseline and final measurements). The PANSS is a 30-item rating scale widely used in assessment of medication effects in schizophrenia. The PANSS ranges from 30-210, with lower scores showing less symptoms. Larger change is better.</description>
        <time_frame>Measured at Week 4</time_frame>
        <population>Study completers</population>
        <group_list>
          <group group_id="O1">
            <title>D-serine 30 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
          <group group_id="O2">
            <title>D-serine 60 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
          <group group_id="O3">
            <title>D Serine 120 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Positive and Negative Symptoms Scale (PANSS)</title>
          <description>Absolute Change in PANSS over four weeks (change between baseline and final measurements). The PANSS is a 30-item rating scale widely used in assessment of medication effects in schizophrenia. The PANSS ranges from 30-210, with lower scores showing less symptoms. Larger change is better.</description>
          <population>Study completers</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="5.3"/>
                    <measurement group_id="O2" value="4.4" spread="8.9"/>
                    <measurement group_id="O3" value="6.3" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>These are paired t test baseline vs final for the 30 mg/kg dose</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>These are paired t test baseline vs final for the 60 mg/kg dose</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>These are paired t test baseline vs final for the 120 mg/kg dose</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery</title>
        <description>Change over 4 weeks. The MATRICS is a scale measuring cognition, and reported as T-score, with 50 as the population average and every 10 points representing a change of 1 standard deviation from the population average. Higher scores represent an improvement</description>
        <time_frame>Measured at Week 4</time_frame>
        <population>study completers</population>
        <group_list>
          <group group_id="O1">
            <title>D-serine 30 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
          <group group_id="O2">
            <title>D-serine 60 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
          <group group_id="O3">
            <title>D Serine 120 mg/kg</title>
            <description>4 weeks of adjunctive treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery</title>
          <description>Change over 4 weeks. The MATRICS is a scale measuring cognition, and reported as T-score, with 50 as the population average and every 10 points representing a change of 1 standard deviation from the population average. Higher scores represent an improvement</description>
          <population>study completers</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.0"/>
                    <measurement group_id="O2" value="3.9" spread="3.5"/>
                    <measurement group_id="O3" value="2.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>These are paired t test baseline vs final for 30mg/kg</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>These are paired t test baseline vs final for 60mg/kg</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>These are paired t test baseline vs final for 120mg/kg</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>D-serine 30 mg/kg</title>
          <description>4 weeks of adjunctive treatment</description>
        </group>
        <group group_id="E2">
          <title>D-serine 60 mg/kg</title>
          <description>4 weeks of adjunctive treatment</description>
        </group>
        <group group_id="E3">
          <title>D Serine 120 mg/kg</title>
          <description>4 weeks of adjunctive treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>2+ proteinuria without glycosuria during the final week of treatment with no significant change in creatinine that resolved following dserine discontinuation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>asymptomatic transaminitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Open Label</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Daniel Javitt</name_or_title>
      <organization>Nathan Kline Institute</organization>
      <phone>845-398-6534</phone>
      <email>javitt@nki.rfmh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

